Please login to the form below

Not currently logged in

Former Amgen EVP Roger Perlmutter joins Heptares board

Also has experience at Merck & Co

Roger Perlmutter, HeptaresHeptares has appointed Amgen's former executive VP, R&D, Dr Roger Perlmutter, to its board of directors.

UK-based Heptares, which focuses on researching medicines that target G protein-coupled receptors across a range of conditions, has made several deals recently with large pharma companies, including AstraZeneca and Shire, and is looking to Dr Perlmutter to help ensure their success.

“We are delighted to welcome Roger to our Board and look forward to benefiting from his extensive US, big biotech and big pharma experience as Heptares advances its pipeline into clinical development,” said John Berriman, Heptares' chair.

Dr Perlmutter served in his executive VP position at Amgen from 2001 to 2012 following a spell at Merck & Co where he was executive VP of worldwide basic research and preclinical development.

Prior to joining Merck in 1997, he was professor and sounding chair of the department of immunology at the University of Washington in Seattle, US.

Dr Perlmutter said: “Heptares has pioneered structure determination in GPCRs, and has used this information to develop leading therapeutic candidates in metabolic and neuropsychiatric disease.

“I am eager to help Malcolm Weir and his team translate these impressive assets into novel therapeutics that will make a difference for patients around the world.”

23rd October 2012

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Seven Stones Total Health

Seven Stones is a creative, independent healthcare communications agency focused on delivering great work combined with patient involvement and support...

Latest intelligence

Revisiting Instagram for pharma
In pharma, Instagram usage is increasing because it offers so many benefits to engage with patients and HCPs...
The one multichannel question you must ask
There is a question every marketer should ask when designing a multichannel communications strategy...
Medius Deal Watch
Deal Watch September 2016
Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up...